Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Evoke Pharma Inc's Business Segments
Evoke Pharma Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2025
Reportable Segments
1
Largest Segment
Pharmaceutical Products
Total Revenue
$ 4
Regions Reported
-
Revenue Share by Reportable Segment - Q3 FY2025
- Pharmaceutical Products0%
Revenue by Reportable Segment - Q3 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Pharmaceutical Products | $ 4 | - |
Description of Evoke Pharma Inc
Evoke Pharma Inc. is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products for the treatment of gastrointestinal (GI) disorders. The company was founded in 2007 and is headquartered in Solana Beach, California.
Evoke Pharma's primary product candidate is Gimoti, a novel nasal spray formulation of metoclopramide, which is being developed for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (DG). Gastroparesis is a condition characterized by delayed emptying of the stomach, leading to symptoms such as nausea, vomiting, reflux, and abdominal pain. There is currently no FDA-approved treatment specifically designed for DG.
Gimoti is designed to deliver metoclopramide, a prokinetic agent that enhances gastric emptying, through a nasal route, bypassing the GI tract. This innovative delivery method helps patients who have difficulty swallowing or retaining oral medication due to GI motility disorders. The nasal spray formulation is expected to provide rapid relief of symptoms and improve patient compliance compared to traditional oral treatments.
Evoke Pharma has conducted clinical trials to evaluate the safety and efficacy of Gimoti in patients with DG. These trials have shown promising results, demonstrating that the nasal spray formulation effectively improves symptoms of DG without causing significant adverse events. The company has also conducted pharmacokinetic studies to determine the drug's absorption, distribution, metabolism, and excretion.
In addition to Gimoti, Evoke Pharma is working on developing other product candidates for the treatment of GI disorders with unmet medical needs. The company is focused on leveraging its expertise in drug delivery technologies to develop innovative solutions that improve patient outcomes.
Evoke Pharma is actively engaged in regulatory and commercialization activities for Gimoti. The company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Gimoti. If approved, Gimoti will be the first nasal spray formulation of metoclopramide available for the treatment of DG.
The company's management team comprises experienced professionals with extensive expertise in pharmaceutical development, clinical operations, regulatory affairs, and commercialization. They are focused on executing the company's strategy and bringing novel treatments to patients suffering from GI disorders.
Overall, Evoke Pharma Inc. is a biopharmaceutical company dedicated to developing innovative treatments for GI disorders. With a focus on nasal drug delivery technology, the company aims to provide effective and convenient solutions for patients with unmet medical needs.
Evoke Pharma's primary product candidate is Gimoti, a novel nasal spray formulation of metoclopramide, which is being developed for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (DG). Gastroparesis is a condition characterized by delayed emptying of the stomach, leading to symptoms such as nausea, vomiting, reflux, and abdominal pain. There is currently no FDA-approved treatment specifically designed for DG.
Gimoti is designed to deliver metoclopramide, a prokinetic agent that enhances gastric emptying, through a nasal route, bypassing the GI tract. This innovative delivery method helps patients who have difficulty swallowing or retaining oral medication due to GI motility disorders. The nasal spray formulation is expected to provide rapid relief of symptoms and improve patient compliance compared to traditional oral treatments.
Evoke Pharma has conducted clinical trials to evaluate the safety and efficacy of Gimoti in patients with DG. These trials have shown promising results, demonstrating that the nasal spray formulation effectively improves symptoms of DG without causing significant adverse events. The company has also conducted pharmacokinetic studies to determine the drug's absorption, distribution, metabolism, and excretion.
In addition to Gimoti, Evoke Pharma is working on developing other product candidates for the treatment of GI disorders with unmet medical needs. The company is focused on leveraging its expertise in drug delivery technologies to develop innovative solutions that improve patient outcomes.
Evoke Pharma is actively engaged in regulatory and commercialization activities for Gimoti. The company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Gimoti. If approved, Gimoti will be the first nasal spray formulation of metoclopramide available for the treatment of DG.
The company's management team comprises experienced professionals with extensive expertise in pharmaceutical development, clinical operations, regulatory affairs, and commercialization. They are focused on executing the company's strategy and bringing novel treatments to patients suffering from GI disorders.
Overall, Evoke Pharma Inc. is a biopharmaceutical company dedicated to developing innovative treatments for GI disorders. With a focus on nasal drug delivery technology, the company aims to provide effective and convenient solutions for patients with unmet medical needs.
Evoke Pharma Inc. is a biopharmaceutical company specializing in the development of innovative treatments for gastrointestinal (GI) disorders. Below is an extensive overview of the segments, products, and services the company offers.
1. Therapeutic Segments
Evoke Pharma focuses primarily on gastrointestinal (GI) disorders, particularly those that affect the motility of the GI tract. Their therapeutic segments include:
- Gastroparesis: A condition characterized by delayed gastric emptying, often resulting in symptoms such as nausea, vomiting, and abdominal pain. This condition is particularly common in diabetic patients.
- Chronic Nausea and Vomiting: These symptoms can result from various gastrointestinal dysfunctions, requiring targeted therapies to manage patient discomfort and improve quality of life.
Key Products
Evoke Pharmas flagship product is GIMOTI™ (metoclopramide) nasal spray, approved for the treatment of gastroparesis in adults. This product is notable for its unique delivery system:
- GIMOTI™: This is a metoclopramide formulation delivered via a nasal spray, which provides a non-invasive alternative to oral medications. GIMOTI™ acts rapidly to facilitate gastric emptying and reduce the symptoms associated with gastroparesis. Its unique formulation may be particularly advantageous for patients who struggle with oral medication due to nausea or vomiting.
Product Pipeline
Beyond GIMOTI™, Evoke Pharma is engaged in research and development of other potential therapeutic candidates targeting various GI disorders. Although specific pipeline products may evolve, the focus typically involves expanding indications for existing therapies or exploring novel formulations that enhance patient compliance and efficacy.
Research and Development Services
Evoke Pharma is dedicated to ongoing research and development, which may include:
- Clinical Trials: The company conducts various clinical studies to rigorously test the safety and efficacy of its products. These trials are crucial for gaining regulatory approvals and may explore different patient demographics and comorbid conditions.
- Formulation Development: The company invests in the creation of new drug formulations that could potentially provide better absorption, faster onset of action, or improved stability compared to existing treatments.
Educational and Support Services
To enhance patient outcomes, Evoke Pharma may also offer educational resources and support services aimed at healthcare professionals and patients:
- Patient Education: Initiatives to inform patients about gastroparesis, its symptoms, and the available treatments, including guidance on the use of GIMOTI™.
- Healthcare Provider Support: Providing resources to healthcare professionals to ensure they are informed about the latest advancements in treating GI disorders and how to best utilize Evoke Pharma’s products.
Regulatory Expertise
Evoke Pharmas team possesses significant expertise in navigating the regulatory landscape, which is essential for developing new pharmaceuticals. This includes:
- Compliance and Quality Assurance: Ensuring that all products meet the stringent regulatory requirements set forth by the FDA and other governing bodies.
- Post-Marketing Surveillance: Monitoring the safety and effectiveness of their products after they reach the market, as well as gathering feedback from healthcare professionals and patients.
Collaborative Initiatives
Evoke Pharma may also engage in collaborations with academic institutions, other biopharmaceutical companies, and research organizations aimed at advancing the understanding and treatment of GI disorders. These collaborations can provide insights that inform product development and clinical practices.
Conclusion
Evoke Pharma Inc. is a focused biopharmaceutical entity that plays a vital role in addressing unmet medical needs in gastrointestinal disorders, particularly gastroparesis. Through its innovative products like GIMOTI™, a robust research pipeline, educational initiatives, and regulatory expertise, the company aims to improve the quality of life for patients suffering from these debilitating conditions.
1. Therapeutic Segments
Evoke Pharma focuses primarily on gastrointestinal (GI) disorders, particularly those that affect the motility of the GI tract. Their therapeutic segments include:
- Gastroparesis: A condition characterized by delayed gastric emptying, often resulting in symptoms such as nausea, vomiting, and abdominal pain. This condition is particularly common in diabetic patients.
- Chronic Nausea and Vomiting: These symptoms can result from various gastrointestinal dysfunctions, requiring targeted therapies to manage patient discomfort and improve quality of life.
Key Products
Evoke Pharmas flagship product is GIMOTI™ (metoclopramide) nasal spray, approved for the treatment of gastroparesis in adults. This product is notable for its unique delivery system:
- GIMOTI™: This is a metoclopramide formulation delivered via a nasal spray, which provides a non-invasive alternative to oral medications. GIMOTI™ acts rapidly to facilitate gastric emptying and reduce the symptoms associated with gastroparesis. Its unique formulation may be particularly advantageous for patients who struggle with oral medication due to nausea or vomiting.
Product Pipeline
Beyond GIMOTI™, Evoke Pharma is engaged in research and development of other potential therapeutic candidates targeting various GI disorders. Although specific pipeline products may evolve, the focus typically involves expanding indications for existing therapies or exploring novel formulations that enhance patient compliance and efficacy.
Research and Development Services
Evoke Pharma is dedicated to ongoing research and development, which may include:
- Clinical Trials: The company conducts various clinical studies to rigorously test the safety and efficacy of its products. These trials are crucial for gaining regulatory approvals and may explore different patient demographics and comorbid conditions.
- Formulation Development: The company invests in the creation of new drug formulations that could potentially provide better absorption, faster onset of action, or improved stability compared to existing treatments.
Educational and Support Services
To enhance patient outcomes, Evoke Pharma may also offer educational resources and support services aimed at healthcare professionals and patients:
- Patient Education: Initiatives to inform patients about gastroparesis, its symptoms, and the available treatments, including guidance on the use of GIMOTI™.
- Healthcare Provider Support: Providing resources to healthcare professionals to ensure they are informed about the latest advancements in treating GI disorders and how to best utilize Evoke Pharma’s products.
Regulatory Expertise
Evoke Pharmas team possesses significant expertise in navigating the regulatory landscape, which is essential for developing new pharmaceuticals. This includes:
- Compliance and Quality Assurance: Ensuring that all products meet the stringent regulatory requirements set forth by the FDA and other governing bodies.
- Post-Marketing Surveillance: Monitoring the safety and effectiveness of their products after they reach the market, as well as gathering feedback from healthcare professionals and patients.
Collaborative Initiatives
Evoke Pharma may also engage in collaborations with academic institutions, other biopharmaceutical companies, and research organizations aimed at advancing the understanding and treatment of GI disorders. These collaborations can provide insights that inform product development and clinical practices.
Conclusion
Evoke Pharma Inc. is a focused biopharmaceutical entity that plays a vital role in addressing unmet medical needs in gastrointestinal disorders, particularly gastroparesis. Through its innovative products like GIMOTI™, a robust research pipeline, educational initiatives, and regulatory expertise, the company aims to improve the quality of life for patients suffering from these debilitating conditions.